Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: Results from a multicenter study (REBECCA) nested within a compassionate use program.[BMC Cancer. 2016;16:412. doi: 10.1186/s12885-016-2440-9.]

Antoine Adenis; Christelle de la Fouchardiere; Bernard Paule; Pascal Burtin; David Tougeron; Jennifer Wallet; Louis Marie Dourthe; Pierre Luc Etienne; Laurent Mineur; Stéphanie Clisant; Jean Marc Phelip; Andrew Kramar; Thierry Andre

ArticleOPEN ACCESS

Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: Results from a multicenter study (REBECCA) nested within a compassionate use program.[BMC Cancer. 2016;16:412. doi: 10.1186/s12885-016-2440-9.]

Adenis A
de la Fouchardiere C
Paule B
et al.

BMC Cancer

DOI: 10.1186/s12885-016-2559-8

9Citations

10Readers

Cite

CITATION STYLE

APA

Adenis, A., de la Fouchardiere, C., Paule, B., Burtin, P., Tougeron, D., Wallet, J., … Andre, T. (2016, July 25). Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: Results from a multicenter study (REBECCA) nested within a compassionate use program.[BMC Cancer. 2016;16:412. doi: 10.1186/s12885-016-2440-9.]. BMC Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12885-016-2559-8

Cite

Register to see more suggestions